Goodwill and Other Intangible Assets Goodwill and Other Intangible Assets (Tables)

12 Months Ended

Dec. 31, 2020

Goodwill and Intangible Assets Disclosure [Abstract]

Schedule of Intangible Assets and Goodwill [Table Text Block]

	As of December 31, 2020				As of December 31, 2019
(in millions)	Gross Carrying Amount		Accumulated Amortization/Goodwill Impairment Charges		Gross Carrying Amount		Accumulated Amortization/Goodwill Impairment Charges
Technology-related	$	11,059	$	(6,179)	$	12,020	$	(5,706)
Patents	511		(407)		525		(408)
Other intangible assets	1,775		(1,220)		1,754		(1,081)
Amortizable intangible assets	$	13,345	$	(7,806)	$	14,299	$	(7,195)
Goodwill	$	19,924	$	(9,973)	$	20,076	$	(9,900)
IPR&D	257				662
Technology-related	120				120
Indefinite-lived intangible assets	$	377			$	782

Schedule of Goodwill [Table Text Block]

The following represents our goodwill balance by global reportable segment and our separately presented Specialty Pharmaceuticals operating segment:

(in millions)	MedSurg		Rhythm and Neuro		Cardiovascular		Specialty Pharmaceuticals		Total
Balance as of December 31, 2018	$	2,063	$	1,924	$	3,925	$	—	$	7,911
Foreign currency fluctuations and other changes	(1)		—		58		9		66
Goodwill acquired	—		268		1,712		238		2,218
Goodwill divested	—		—		(19)		—		(19)
Balance as of December 31, 2019	$	2,061	$	2,192	$	5,676	$	247	$	10,176
Foreign currency fluctuations and other changes	(2)		3		22		—		22
Goodwill impairment charges	—		—		—		(73)		(73)
Goodwill reclassified to Current assets held for sale	—		—		—		(175)		(175)
Balance as of December 31, 2020	$	2,059	$	2,194	$	5,697	$	—	$	9,951

Schedule of Expected Amortization Expense [Table Text Block]

Estimated Amortization expense for each of the five succeeding fiscal years based upon our amortizable intangible asset portfolio as of December 31, 2020 is as follows (in millions):

Fiscal Year
2021	$	689
2022	664
2023	651
2024	613
2025	560